iBio (NASDAQ:IBIO – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for iBio and Opus Genetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iBio | 1 | 0 | 4 | 3 | 3.12 |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
iBio presently has a consensus price target of $5.00, suggesting a potential upside of 281.68%. Opus Genetics has a consensus price target of $10.69, suggesting a potential upside of 128.96%. Given iBio’s stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Opus Genetics.
Volatility and Risk
Insider and Institutional Ownership
7.9% of iBio shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares iBio and Opus Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iBio | N/A | -40.66% | -35.78% |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
Valuation & Earnings
This table compares iBio and Opus Genetics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iBio | $100,000.00 | 842.46 | -$33.04 million | ($0.34) | -3.85 |
| Opus Genetics | $14.20 million | 27.18 | -$49.59 million | ($1.35) | -3.46 |
iBio has higher earnings, but lower revenue than Opus Genetics. iBio is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Summary
iBio beats Opus Genetics on 10 of the 15 factors compared between the two stocks.
About iBio
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
